ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1779

CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation

Cuong Nguyen1, Dai Hui 1, Ran Gu 1, Trevor Chan 2, Alina Marleev 3, Emanual Maverakis 3, Vijay Kuchroo 4, Shie-Liang Hsieh 5, Ilias Tagkopoulos 2, Christopher Ritchlin 6 and Iannis Adamopoulos 1, 1Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Sacramento, CA, 2University of California, Davis, Department of Computer Science, California, USA, Davis, CA, 3Department of Dermatology, School of Medicine, UCD, Sacramento, California, USA., Sacramento, CA, 4Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, MA, USA, Boston, MA, 5Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei, Taiwan, Taipei, Taiwan (Republic of China), 6Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: arthritis and psoriatic arthritis, Interleukin-23, MDL-1, skin inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Interleukin-23 (IL-23) and its cognate receptor interleukin-23R (IL-23R):IL-12Rβ1 plays a critical role in the pathogenesis of autoimmune diseases including psoriasis and psoriatic arthritis. Although significance of IL-23 signaling in adaptive immunity has been well-studied, the role of IL-23 in myeloid cell activation remains unknown.

Methods: To investigate role of CLEC5A/MDL-1 in psoriatic arthritis-like pathology, we performed in vivo gene transfer of IL-23 in WT, IL-23RGFP reporter, and Mdl-1-/- mice. qRT-PCR, RNAseq, Western blot, flow cytometry, ELISA, H&E stain, and immunofluorescence staining methods were used to analyze the phenotype of WT and transgenic mice.

Results: Herein, we show in the IL-23RGFP reporter mice, that IL-23 induces the expansion of myeloid cell populations including an epidermal myeloid DNAX activation protein 12 (DAP12)-associating lectin-1 (MDL-1)+CD11b+Ly6G+IL-23R+ cell population associated with epidermal hyperplasia and an MDL-1+CD11b+Ly6ChighIL-23R+ associated with bone destruction. Mechanistically, genetic ablation of MDL-1 prevented IL-23-gene transfer elicited myelopoiesis and showed a marked reduction of skin inflammation markers (K16, S100a7, S100a8, S100a9, Cxcl-1, Cxcl-2) and bone destruction markers (Acp5, Ctsk, Mmp9) compared to wildtype mice. Moreover, we found that Mdl-1-/- mice had significantly higher bone mass and impaired osteoclast differentiation in vitro and in vivo as well as reduced joint inflammation in IL-23 gene transfer induced arthritis. Mechanistic data through of flow cytometry, Western blotting and co-immunoprecipitation experiments revealed that a trimeric complex of IL-23R/DAP12/MDL-1 elicited the associated pathologies in our murine model. Furthermore, we performed RNAseq analysis of murine skin following IL-23 gene transfer and revealed 297 differentially expressed genes (DEGs) affected by MDL-1 deletion. Specifically, these DEGs are associated with myelopoiesis, neutrophil proteases, DAP12, cell survival and apoptosis. We correlated our findings with RNAseq meta-analyses derived from human psoriatic skin (135 patients vs 133 controls), which showed elevation of MDL-1 in psoriatic patients and positive correlation for IL-23 versus MDL-1 and IL-23R versus MDL-1.

Conclusion: Collectively, our data demonstrate that MDL-1 is a critical component of IL-23 signaling that dictates synovial and skin inflammation in vivo, and could be targeted for the treatment of PsA.


Disclosure: C. Nguyen, None; D. Hui, None; R. Gu, None; T. Chan, None; A. Marleev, None; E. Maverakis, None; V. Kuchroo, None; S. Hsieh, None; I. Tagkopoulos, None; C. Ritchlin, AbbVie, 2, 5, 9, Amgen, 2, 5, BMS, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Lilly, 5, Novartis, 5, Pfizer, 2, Pfizer Inc, 5, UCB, 2, 5; I. Adamopoulos, None.

To cite this abstract in AMA style:

Nguyen C, Hui D, Gu R, Chan T, Marleev A, Maverakis E, Kuchroo V, Hsieh S, Tagkopoulos I, Ritchlin C, Adamopoulos I. CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clec5a-mdl-1-is-critical-for-inflammatory-arthritis-and-skin-inflammation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clec5a-mdl-1-is-critical-for-inflammatory-arthritis-and-skin-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology